Drugs / SNAC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02920385 | Oct 2016 → Apr 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-06 | Novo Nordisk A/S | Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology novonordisk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02920385 ↗ |
| Route | Oral | “Oral administration once daily alone or together with levothyroxine or semaglutide” NCT02920385 ↗ |